- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07691515
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (RAINBOW)
Transcatheter Arterial Chemoembolization in Combination With Tislelizumab Plus Lenvatinib Versus Systemic Cisplatin Plus Gemcitabine in Combination With Tislelizumab for Unresectable Intrahepatic Cholangiocarcinoma: A Phase III, Multicenter, Randomized Controlled Trial
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab as first-line treatment for patients with unresectable intrahepatic cholangiocarcinoma.
Approximately 140 eligible patients with histologically confirmed unresectable intrahepatic cholangiocarcinoma without extrahepatic metastasis will be enrolled and randomized in a 1:1 ratio to receive either TACE plus tislelizumab and lenvatinib or GEMCIS plus tislelizumab. In the TACE-based treatment arm, hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to the protocol.
The primary endpoint is overall survival. Secondary endpoints include progression-free survival, time to progression, objective response rate, disease control rate, safety, and quality of life.
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Gaojun Teng, MD
- Numero di telefono: +86 13805171500
- Email: gjteng@seu.edu.cn
Backup dei contatti dello studio
- Nome: Binyan Zhong, MD
- Numero di telefono: +86 15850522044
- Email: byzhongir@sina.com
Luoghi di studio
-
-
Guangdong
-
Guangzhou, Guangdong, Cina, 510060
- The First Affiliated Hospital, Sun Yat-sen University
-
Contatto:
- Ming Kuang
- Numero di telefono: 020-87755766
- Email: kuangm@mail.sysu.edu.cn
-
Contatto:
- Zhenwei Peng
- Email: pzhenw@mail.sysu.edu.cn
-
Sub-investigatore:
- Wenzhe Fan
-
Guangzhou, Guangdong, Cina, 510317
- Guangdong Second People's Hospital
-
Contatto:
- Chengjiang Xiao
- Numero di telefono: +86 13602808387
- Email: Xxx196610@163.com
-
Guangzhou, Guangdong, Cina, 510168
- Jinshazhou Hospital of Guangzhou University of Chinese Medicine
-
Contatto:
- Liangliang Qiao
- Numero di telefono: +86 13544539881
- Email: 271937316@qq.com
-
Guangzhou, Guangdong, Cina, 511400
- The Affiliated Panyu Central Hospital of Guangzhou Medical University
-
Contatto:
- Fuxi Huang
- Numero di telefono: +86 18902299938
- Email: Fuxihuang2006@126.com
-
Guangzhou, Guangdong, Cina, 524003
- The Second Affiliated Hospital of Guangdong Medical University
-
Contatto:
- Kangshun Zhu
- Numero di telefono: +86 13602864242
- Email: Zhksh010@163.com
-
Jiangmen, Guangdong, Cina, 529030
- Jiangmen Central Hospital
-
Contatto:
- Yuchuang Liang
- Numero di telefono: +86 13322888181
- Email: jmlyc@21cn.com
-
-
Hubei
-
Wuhan, Hubei, Cina, 430022
- Wuhan Union Hospital of China
-
Contatto:
- Xuefeng Kan
- Numero di telefono: +86 13545874189
- Email: xkliulang1314@163.com
-
-
Hunan
-
Changsha, Hunan, Cina, 410013
- The Third XIANGYA Hospital of Central South University
-
Contatto:
- Qi Liang
- Numero di telefono: +86 137 8731 8180
- Email: csuliangqi10@163.com
-
Changsha, Hunan, Cina, 410011
- The Second Xiangya Hospital of Central South University
-
Contatto:
- Yudong Xiao
- Numero di telefono: +86 136 3740 3027
- Email: xiaoyudong222@csu.edu.cn
-
-
Jiangxi
-
Ganzhou, Jiangxi, Cina, 341000
- Ganzhou Hospital-Nanfang Hospital, Southern Medical University
-
Contatto:
- Yusheng Song
- Numero di telefono: +86 135 7675 2988
- Email: 646993126@qq.com
-
Nanchang, Jiangxi, Cina, 330209
- The First Affiliated Hospital of Nanchang University
-
Contatto:
- Junhua Ai
- Numero di telefono: +86 18170936163
- Email: aijh0001@163.com
-
-
Shandong
-
Qingdao, Shandong, Cina, 266000
- The Affiliated Hospital of Qingdao University
-
Contatto:
- Song Wang
- Numero di telefono: +86 18661805592
- Email: derekqyfy@126.com
-
-
Sichuan
-
Chengdu, Sichuan, Cina, 610041
- West China School of Medicine/West China Hospital, Sichuan University (WCSM/WCH, SCU)
-
Contatto:
- Chang Liu
- Numero di telefono: +86 18980606382
- Email: drliuchang@wchscu.cn
-
-
Zhejiang
-
Hangzhou, Zhejiang, Cina, 310022
- Zhejiang Cancer Hospital
-
Contatto:
- Gaojun Teng
- Numero di telefono: +86 0571 - 88122222
- Email: gjteng@seu.edu.cn
-
Contatto:
- Binyan Zhong
- Numero di telefono: +86 15850522044
- Email: byzhongir@sina.com
-
Sub-investigatore:
- Jiaping Zheng
-
Jinhua, Zhejiang, Cina, 321000
- Jinhua Municipal Central Hospital
-
Contatto:
- Xiaogang Hu
- Numero di telefono: +86 135 8866 8173
- Email: heartdoctor@163.com
-
Lishui, Zhejiang, Cina, 323020
- Lishui Central Hospital
-
Contatto:
- Jiansong Ji
- Numero di telefono: +86 0578-2285888
- Email: jjstcty@sina.com
-
Contatto:
- Jianfei Tu
- Email: jianfei1133@163.com
-
Ningbo, Zhejiang, Cina, 315010
- Ningbo No.2 Hospital
-
Contatto:
- Yunjie Chen
- Numero di telefono: +86 13857877137
- Email: a88960317@163.com
-
Ningbo, Zhejiang, Cina, 315048
- Ningbo Medical Center Lihuili Hospital
-
Contatto:
- Shengdong Wu
- Numero di telefono: +86 13567886669
- Email: 13567886669@139.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed intrahepatic cholangiocarcinoma that is unresectable or recurrent after curative treatment, without extrahepatic metastasis.
- No prior systemic therapy or transarterial interventional therapy for intrahepatic cholangiocarcinoma.
- At least one measurable intrahepatic lesion according to RECIST v1.1.
- ECOG performance status of 0 or 1.
- Child-Pugh class A liver function.
- Life expectancy ≥3 months.
Adequate hematologic, hepatic, renal, and thyroid function within 14 days before study start, defined as:
- Absolute neutrophil count ≥1.5 × 10⁹/L;
- Platelet count ≥75 × 10⁹/L;
- Hemoglobin ≥90 g/L;
- Serum albumin ≥30 g/L;
- Total bilirubin ≤1.5 × upper limit of normal;
- AST and ALT <1.5 × upper limit of normal, and ALP <4 × upper limit of normal;
- TSH <1 × upper limit of normal, with T3 and T4 within the normal range;
- Serum creatinine <1.5 × upper limit of normal and creatinine clearance ≥60 mL/min.
Exclusion Criteria:
- Diffuse infiltrative liver lesions.
- Contraindications to TACE.
- Allergy to intravenous contrast agent.
- pregnant or breastfeeding women, or participants planning pregnancy within 2 years / unwilling to use effective contraception.
- Patients with HIV or syphilis infection.
- Patients with concurrent malignancies or other malignancies within 5 years before enrollment.
- History of allogeneic organ transplantation.
- Severe dysfunction of the heart, kidney, or other organs.
- Severe clinically active infection > grade 2 according to NCI-CTC v5.0.
- Psychiatric illness that may affect the informed consent process; Inability to take oral medications; Participation in another drug clinical trial within 12 months before enrollment.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: TACE Plus Tislelizumab and Lenvatinib
Participants will receive tislelizumab 200 mg intravenously every 3 weeks and oral lenvatinib once daily at a starting dose of 12 mg for body weight ≥60 kg or 8 mg for body weight <60 kg.
TACE will be performed after initiation of lenvatinib and may be repeated based on radiologic response, residual viable tumor, liver function, and investigator assessment.
Both conventional TACE (cTACE) and drug-eluting beads TACE are allowed, and hepatic artery infusion chemotherapy may be added at investigator's discretion.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Oral lenvatinib once daily, 12 mg for participants with body weight ≥60 kg or 8 mg for participants with body weight <60 kg, with dose modification according to toxicity.
Conventional TACE or drug-eluting bead TACE are allowed.
TACE may be repeated based on imaging assessment every 6 weeks ±7 days and investigator judgment.
Optional hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to protocol-defined dose ranges.
|
|
Comparatore attivo: Gemcitabine-Cisplatin Plus Tislelizumab
Participants will receive cisplatin 25 mg/m² on Day 1 and Day 8, gemcitabine 1000 mg/m² on Days 1 and 8, and tislelizumab 200 mg on Day 1 of each 3-week cycle for up to 8 cycles.
After completion of gemcitabine-cisplatin treatment, participants will continue tislelizumab 200 mg intravenously every 3 weeks.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Gemcitabine 1000 mg/m² intravenously on Days 1 and 8 of each 21-day cycle, up to 8 cycles.
Cisplatin 25 mg/m² intravenously on Day 1 and Day 8 of each 21-day cycle, up to 8 cycles.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival
Lasso di tempo: From randomization to death from any cause, assessed up to approximately 48 months
|
Overall survival is defined as the time from enrollment/randomization to death from any cause.
Participants who withdraw are lost to follow-up or remain alive at the end of the study will be censored at the date they were last known to be alive.
|
From randomization to death from any cause, assessed up to approximately 48 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-Free Survival
Lasso di tempo: From randomization to disease progression or death, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression or death from any cause.
Participants without progression or death will be censored at the last date known to be progression-free.
|
From randomization to disease progression or death, assessed up to approximately 48 months
|
|
Time to Progression
Lasso di tempo: From randomization to disease progression, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression.
Participants who die without prior progression, withdraw, are lost to follow-up, or remain progression-free at study end will be censored at the last date known to be progression-free.
|
From randomization to disease progression, assessed up to approximately 48 months
|
|
Objective Response Rate
Lasso di tempo: Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response or partial response according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Disease Control Rate
Lasso di tempo: Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response, partial response, or stable disease according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Incidence of Grade ≥3 Adverse Events
Lasso di tempo: From first dose of study treatment through 28 days after the last dose of study treatment
|
Defined as the occurrence of grade 3 or higher hematologic or non-hematologic toxicities, graded according to CTCAE v5.0.
|
From first dose of study treatment through 28 days after the last dose of study treatment
|
|
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Lasso di tempo: Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 is a 30-item questionnaire used to assess health-related quality of life in patients with cancer.
Scores are linearly transformed to a 0 to 100 scale.
For the global health status/quality-of-life scale and functional scales, higher scores indicate better health-related quality of life or functioning.
For symptom scales and single symptom items, higher scores indicate a higher symptom burden or worse symptoms.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
|
Quality of Life Assessed by the EuroQol Five-Dimension (EQ-5D)
Lasso di tempo: Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The EuroQol Five-Dimension Three-Level Questionnaire is a standardized instrument for measuring health-related quality of life.
The descriptive system includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension is scored from 1 to 3, where 1 indicates no problems, 2 indicates some or moderate problems, and 3 indicates extreme problems or inability to perform the activity.
Higher scores in each dimension indicate more severe problems or worse health status.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Gaojun Teng, MD, Zhejiang Cancer Hospital
- Investigatore principale: Min Kuang, MD, First Affiliated Hospital, Sun Yat-Sen University
- Investigatore principale: Jiansong Ji, MD, The Central Hospital of Lishui City
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Carcinoma
- Colangiocarcinoma
- Cirrosi, familiare, con ipertensione polmonare
- Composti eterociclici, 1-anello
- Composti eterociclici
- Prodotti chimici inorganici
- Composti di cloro
- Composti di azoto
- Deossictidina
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Composti di platino
- Gemcitabina
- Cisplatino
- Lenvatinib
- tislelizumab
Altri numeri di identificazione dello studio
- RAINBOW 01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .